Insider Trading Roundup: Atossa Genetics (ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) insider has recently participated in insider trading activity. President & CEO, QUAY STEVEN C bought 15,000 shares for $ 7,950 via one transaction Feb 16. Following the transaction, the insider now owns 4,811,858 shares in total, priced at $3175826.28 as of Wednesday. Another notable insider trading was done by the same insider on Jan 19. QUAY STEVEN C acquired 50,000 shares at an average price of $0.20 for a total of $10,000. Director, Chen Shu-Chih bought 15,000 shares for $7,950 via one transaction Feb 16. Following the transaction, the insider now owns 4,333,315  shares in total, priced at $2859987.9 as of Wednesday. Another notable insider trading was done by the same insider on Jan 19. Chen Shu-Chih acquired 50,000 shares at an average price of $0.20 for a total of $10,000.

The stock has experienced a total of 4 insider trades in the past three months. These trades include 0 sell activities and 4 buy trades. Furthermore, over the past 12 months, the stock was traded 5 times by insiders. In 0 of these trades, the insider was a seller while an employee of the company was the buyer in just 5 instances.

On December 17, 2015, Atossa Genetics Inc (ATOS) a healthcare company focused on developing locally-administered pharmaceuticals for the treatment of pre-cancerous conditions and early stage breast cancer, announced that on December 16, 2015, it entered into a Stock Purchase Agreement with NRL Investment Group, LLC, an unrelated entity. Under the agreement, Atossa sold to the NRL Group 100% of its shares of Common Stock in its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (the “NRLBH”), while retaining 19% ownership through Preferred Stock. Atossa received $50,000 on December 16, 2015, for the sale of the Common Stock and the right to receive, commencing in December 2016, monthly earn-out payments equal to 6% of gross revenue of the NRLBH, up to a total of $10,000,000. Atossa also has the right in four years to sell its Preferred Stock to the NRL Group for the greater of $4,000,000 or fair market value. As a result of the transaction, the NRL Group is taking over the management, operations and related costs of the NRLBH.

Atossa Genetics Inc. operates as a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer in the United States. The company markets nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator devices that are intended for the collection of NAF for cytological testing at a laboratory.